DHRHealth Institute for Research and Development
News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this medical research study is to determine the effect of once-daily, oral administration of 80 or 100 mg MGL-3196 versus matching placebo on NASH (a placebo looks like the investigational drug but does not contain any of the active ingredients of the investigational drug). The study is open to male and female participants 18 years of age or older who meet the study requirements.


Principal Investigator
Rashmee Patil, MD
Madrigal Pharmaceuticals, Inc
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram